-transparent.png){kind=logo}
The authors compared both therapeutic efficacy and toxicity of two different treatment regimens: ABC = adriamycin, nitrogen mustard (BCNU) and cyclophosphamide (CTX) vs. AC = adriamycin and cyclophosphamide in ovarian cancer. Thirty-one patients were entered under treatment plan ABC and 26 under treatment plan AC simultaneously. Therapeutic evaluation was subdivided into different risk groups (adjuvant therapy, residual disease less than or greater than 2 cm). A similar result could be noted in the two different treatment regimens. Toxicity was more severe and frequent in the group treated with BCNU. The AC regimen was preferred because of its lower incidence of side-effects and for its easier mode of administration.
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
January 1985,
European journal of gynaecological oncology,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
December 1980,
Cancer,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
June 1987,
Lijecnicki vjesnik,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
January 1977,
Cancer treatment reports,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
January 1989,
European journal of gynaecological oncology,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
March 1991,
Cancer treatment reviews,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
December 1978,
European journal of cancer,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
August 1979,
Cancer treatment reports,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
January 1989,
Actas urologicas espanolas,
T Mazzei, and
M Bonazza, and
G Amunni, and
G Scarselli, and
F Branconi, and
G B Massi
January 1992,
Annals of oncology : official journal of the European Society for Medical Oncology,
